| 당뇨병 고위험군 및 내당능장애자에서 Mosapride, 5HT-4 Agonist의 2주간 투여가 인슐린 감수성에 미치는 영향 |
|
남주영, 조민호, 정한영, 윤지은, 남지선, 김혜진, 박종숙, 강은석, 안철우, 차봉수, 송영득, 임승길, 김경래, 이현철 |
|
|
| The Effect of Mosapride, 5HT-4 Agonist on Insulin Sensitivity of Patients with IGT and High Risk Group of Type 2 Diabetes Mellitus |
|
Joo Young Nam, Min Ho Cho, Han Young Jung, Ji Eun Yoon, Ji Sun Nam, Hai Jin Kim, Jong Suk Park, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Young Duk Song, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee |
|
|
| Abstract |
|
Introduction: Mosapride, a benzamide derivative, is widely used in patients with motility disorders as a prokinetic agent. Recent studies suggested that mosapride may modulate the secretion and/or action of insulin through 5HT receptors. So we investigated the potential effect of mosapride on insulin sensitivity in subjects with impaired glucose tolerance, having high risks for Type 2 diabetes mellitus. Methods: Thirty subjects were selected for this study with informed consent (20:mosapride group, 10: placebo control group). Insulin sensitivity was measured by euglycemic Hyperinsulinemic clamp, before and after two weeks of mosapride administration. Results: No difference was found between the two groups in terms of sex, age, BMI, blood pressure, total cholesterol, triglyceride and HDL-cholesterol. After 2 weeks treatment of mosapride, fasting plasma glucose levels and insulin levels were decreased. Follow-up glucose disposal rates were higher than the Initial values, and were comparable to those of control subjects. Conclusion: Mosapride improved insulin action in pre-diabetic subjects and it can be regarded as a supplementary insulin sensitizer. |
| Key Words:
Euglycemic hyperinsulinemic clamp, Insulin resistance, Mosapride |
|
PDF Links
Full text via DOI
Download Citation
